TY - JOUR AU - Yao, J. C. AU - Hassan, M. AU - Phan, A. AU - Dagohoy, C. AU - Leary, C. AU - Mares, J. E. AU - Abdalla, E. K. AU - Fleming, J. B. AU - Vauthey, J. N. AU - Rashid, A. AU - Evans, D. B. PY - 2008 DA - 2008// TI - One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.15.4377 DO - 10.1200/JCO.2007.15.4377 ID - Yao2008 ER - TY - JOUR AU - Halfdanarson, T. R. AU - Rabe, K. G. AU - Rubin, J. AU - Petersen, G. M. PY - 2008 DA - 2008// TI - Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival JO - Ann Oncol VL - 19 UR - https://doi.org/10.1093/annonc/mdn351 DO - 10.1093/annonc/mdn351 ID - Halfdanarson2008 ER - TY - JOUR AU - Kulke, M. H. AU - Bendell, J. AU - Kvols, L. K. AU - Picus, J. AU - Pommier, R. PY - 2011 DA - 2011// TI - Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors JO - J Hematol Oncol VL - 4 UR - https://doi.org/10.1186/1756-8722-4-29 DO - 10.1186/1756-8722-4-29 ID - Kulke2011 ER - TY - JOUR AU - Rinke, A. AU - Michl, P. AU - Gress, T. PY - 2012 DA - 2012// TI - Medical treatment of gastroenteropancreatic neuroendocrine tumors JO - Cancers VL - 4 UR - https://doi.org/10.3390/cancers4010113 DO - 10.3390/cancers4010113 ID - Rinke2012 ER - TY - JOUR AU - Yao, J. C. AU - Phan, A. T. AU - Chang, D. Z. AU - Wolff, R. A. AU - Hess, K. AU - Gupta, S. AU - Jacobs, C. AU - Mares, J. E. AU - Landgraf, A. N. AU - Rashid, A. AU - Meric-Bernstam, F. PY - 2008 DA - 2008// TI - Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2008.16.7858 DO - 10.1200/JCO.2008.16.7858 ID - Yao2008 ER - TY - JOUR AU - Yao, J. C. AU - Lombard-Bohas, C. AU - Baudin, E. AU - Kvols, L. K. AU - Rougier, P. AU - Ruszniewski, P. AU - Hoosen, S. AU - St Peter, J. AU - Haas, T. AU - Lebwohl, D. PY - 2010 DA - 2010// TI - Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.24.2669 DO - 10.1200/JCO.2009.24.2669 ID - Yao2010 ER - TY - JOUR AU - Faivre, S. AU - Delbaldo, C. AU - Vera, K. AU - Robert, C. AU - Lozahic, S. AU - Lassau, N. AU - Bello, C. AU - Deprimo, S. AU - Brega, N. AU - Massimini, G. PY - 2006 DA - 2006// TI - Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.02.2194 DO - 10.1200/JCO.2005.02.2194 ID - Faivre2006 ER - TY - JOUR AU - Kulke, M. H. AU - Lenz, H. J. AU - Meropol, N. J. AU - Posey, J. AU - Ryan, D. P. AU - Picus, J. AU - Bergsland, E. AU - Stuart, K. AU - Tye, L. AU - Huang, X. PY - 2008 DA - 2008// TI - Activity of sunitinib in patients with advanced neuroendocrine tumors JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.15.9020 DO - 10.1200/JCO.2007.15.9020 ID - Kulke2008 ER - TY - STD TI - Afinitor [package insert]. http://www.pharma.us.novartis.com/product/pi/pdf/afinitor.pdf UR - http://www.pharma.us.novartis.com/product/pi/pdf/afinitor.pdf ID - ref9 ER - TY - STD TI - Sutent [package insert]. http://labeling.pfizer.com/ShowLabeling.aspx?id=607 UR - http://labeling.pfizer.com/ShowLabeling.aspx?id=607 ID - ref10 ER - TY - STD TI - Clinical Practice Guideline on Oncology - Neuroendocrine Tumors [http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf] UR - http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf ID - ref11 ER - TY - JOUR AU - Raymond, E. AU - Dahan, L. AU - Raoul, J. L. AU - Bang, Y. J. AU - Borbath, I. AU - Lombard-Bohas, C. AU - Valle, J. AU - Metrakos, P. AU - Smith, D. AU - Vinik, A. PY - 2011 DA - 2011// TI - Sunitinib malate for the treatment of pancreatic neuroendocrine tumors JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1003825 DO - 10.1056/NEJMoa1003825 ID - Raymond2011 ER - TY - CHAP PY - 2011 DA - 2011// TI - Oncology Drugs Advisory - FDA review: sNDA 21,938 BT - Book Oncology Drugs Advisory - FDA review: sNDA 21,938 PB - Food and Drug Administration CY - City ID - ref13 ER - TY - CHAP PY - 2010 DA - 2010// TI - Assessment report for sutent (sunitinib) BT - Book Assessment Report for Sutent (sunitinib) PB - European Medicines Agency CY - City ID - ref14 ER - TY - JOUR AU - Jansen, J. P. AU - Fleurence, R. AU - Devine, B. AU - Itzler, R. AU - Barrett, A. AU - Hawkins, N. AU - Lee, K. AU - Boersma, C. AU - Annemans, L. AU - Cappelleri, J. C. PY - 2011 DA - 2011// TI - Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1 JO - Value Health VL - 14 UR - https://doi.org/10.1016/j.jval.2011.04.002 DO - 10.1016/j.jval.2011.04.002 ID - Jansen2011 ER - TY - JOUR AU - Mills, E. J. AU - Bansback, N. AU - Ghement, I. AU - Thorlund, K. AU - Kelly, S. AU - Puhan, M. A. AU - Wright, J. PY - 2011 DA - 2011// TI - Multiple treatment comparison meta-analyses: a step forward into complexity JO - J Clin Epidemiol VL - 3 UR - https://doi.org/10.2147/CLEP.S16526 DO - 10.2147/CLEP.S16526 ID - Mills2011 ER - TY - JOUR AU - Bucher, H. C. AU - Guyatt, G. H. AU - Griffith, L. E. AU - Walter, S. D. PY - 1997 DA - 1997// TI - The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials JO - J Clin Epidemiol VL - 50 UR - https://doi.org/10.1016/S0895-4356(97)00049-8 DO - 10.1016/S0895-4356(97)00049-8 ID - Bucher1997 ER - TY - JOUR AU - Glenny, A. M. AU - Altman, D. G. AU - Song, F. AU - Sakarovitch, C. AU - Deeks, J. J. AU - D’Amico, R. AU - Bradburn, M. AU - Eastwood, A. J. PY - 2005 DA - 2005// TI - Indirect comparisons of competing interventions JO - Health Technol Assess VL - 9 UR - https://doi.org/10.3310/hta9260 DO - 10.3310/hta9260 ID - Glenny2005 ER - TY - JOUR AU - Sutton, A. AU - Ades, A. E. AU - Cooper, N. AU - Abrams, K. PY - 2008 DA - 2008// TI - Use of indirect and mixed treatment comparisons for technology assessment JO - Pharmacoeconomics VL - 26 UR - https://doi.org/10.2165/00019053-200826090-00006 DO - 10.2165/00019053-200826090-00006 ID - Sutton2008 ER - TY - JOUR AU - Signorovitch, J. E. AU - Wu, E. Q. AU - Yu, A. P. AU - Gerrits, C. M. AU - Kantor, E. AU - Bao, Y. AU - Gupta, S. R. AU - Mulani, P. M. PY - 2010 DA - 2010// TI - Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept JO - Pharmacoeconomics VL - 28 UR - https://doi.org/10.2165/11538370-000000000-00000 DO - 10.2165/11538370-000000000-00000 ID - Signorovitch2010 ER - TY - JOUR AU - Signorovitch, J. E. AU - Wu, E. Q. AU - Swallow, E. AU - Kantor, E. AU - Fan, L. AU - Gruenberger, J. B. PY - 2011 DA - 2011// TI - Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials JO - Clin Drug Investig VL - 31 UR - https://doi.org/10.2165/11592490-000000000-00000 DO - 10.2165/11592490-000000000-00000 ID - Signorovitch2011 ER - TY - JOUR AU - Yao, J. C. AU - Shah, M. H. AU - Ito, T. AU - Bohas, C. L. AU - Wolin, E. M. AU - Van Cutsem, E. AU - Hobday, T. J. AU - Okusaka, T. AU - Capdevila, J. AU - de Vries, E. G. PY - 2011 DA - 2011// TI - Everolimus for advanced pancreatic neuroendocrine tumors JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1009290 DO - 10.1056/NEJMoa1009290 ID - Yao2011 ER - TY - JOUR AU - Parmar, M. K. AU - Torri, V. AU - Stewart, L. PY - 1998 DA - 1998// TI - Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints JO - Stat Med VL - 17 UR - https://doi.org/3.0.CO;2-8 DO - 3.0.CO;2-8 ID - Parmar1998 ER - TY - JOUR AU - Williamson, P. R. AU - Smith, C. T. AU - Hutton, J. L. AU - Marson, A. G. PY - 2002 DA - 2002// TI - Aggregate data meta-analysis with time-to-event outcomes JO - Stat Med VL - 21 UR - https://doi.org/10.1002/sim.1303 DO - 10.1002/sim.1303 ID - Williamson2002 ER - TY - STD TI - Engauge Digitizer. http://digitizer.sourceforge.net/ UR - http://digitizer.sourceforge.net/ ID - ref25 ER - TY - STD TI - Protocol A6181111. http://www.clinicalstudyresults.org/documents/company-study_8958_0.pdf UR - http://www.clinicalstudyresults.org/documents/company-study_8958_0.pdf ID - ref26 ER - TY - JOUR AU - Signorovitch, J. E. AU - Wu, E. Q. AU - Betts, K. A. AU - Parikh, K. AU - Kantor, E. AU - Guo, A. AU - Bollu, V. K. AU - Williams, D. AU - Wei, L. J. AU - DeAngelo, D. J. PY - 2011 DA - 2011// TI - Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials JO - Curr Med Res Opin VL - 27 UR - https://doi.org/10.1185/03007995.2011.576238 DO - 10.1185/03007995.2011.576238 ID - Signorovitch2011 ER - TY - CHAP AU - Hirano, K. AU - Imbens, G. W. AU - Ridder, G. PY - 2000 DA - 2000// TI - Efficient estimation of average treatment effects using the estimated propensity score BT - Book Efficient Estimation of Average Treatment Effects Using the Estimated Propensity Score PB - National Bureau of Economic Research, Inc CY - City ID - Hirano2000 ER - TY - JOUR AU - Kulke, M. H. AU - Siu, L. L. AU - Tepper, J. E. AU - Fisher, G. AU - Jaffe, D. AU - Haller, D. G. AU - Ellis, L. M. AU - Benedetti, J. K. AU - Bergsland, E. K. AU - Hobday, T. J. PY - 2011 DA - 2011// TI - Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.33.2056 DO - 10.1200/JCO.2010.33.2056 ID - Kulke2011 ER - TY - JOUR AU - Adjei, A. A. AU - Christian, M. AU - Ivy, P. PY - 2009 DA - 2009// TI - Novel designs and end points for phase II clinical trials JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-08-2035 DO - 10.1158/1078-0432.CCR-08-2035 ID - Adjei2009 ER -